In preclinical studies, NKCEs have been used effectively in CD33+ acute myeloid leukaemia [231] and myelodysplastic syndromes [232], epidermal growth factor receptor (EGFR) in multiple cancers [233], B cell maturation antigen (BCMA) in multiple myeloma [234], etc. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.